CLEARWATER, Fla.–(BUSINESS WIRE)–Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today reported preliminary revenue results for the full year and fourth quarter ended December 31, 2020.
Preliminary Fourth Quarter 2020 Revenue Summary:
- Total Q4 revenue in a range of approximately $10.9 to $11.3 million, up approximately 30% to 35% year-over-year.
- Advanced Energy revenue in a range of approximately $9.5 to $9.8 million, up approximately 39% to 43% year-over-year.
- OEM revenue in a range of approximately $1.35 to…